Summary
Lincoff et al., NEJM 2023. n=17,604 adults with overweight/obesity and established CV disease without diabetes. 20% MACE reduction at 39.8 months mean follow-up. PMID 37952131.
Source hierarchy
- Peer-reviewed publications in NEJM, Lancet, JAMA, Diabetes Care
- FDA prescribing information and label updates
- Clinicaltrials.gov registered trial protocols
- USP <797>, <71>, <85> pharmacy quality standards
Related clinical pages
Note for patients: Clinical trial data on this site is summarized for general education. Specific dosing decisions, contraindication assessments, and treatment plans must be made with a licensed healthcare provider who has reviewed your full medical history.
